Navigation Links
U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies' SUPERA Peripheral Stent
Date:3/18/2009

Novel Stent Platform Designed for Radial Strength, Flexibility

HOUSTON, March 18 /PRNewswire/ -- IDEV Technologies Incorporated, (IDEV) an emerging leader in the development and marketing of minimally invasive technologies, announced today that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for a multi-center clinical trial of its SUPERA stent, a novel stent platform designed for the treatment of peripheral artery disease (PAD) in the superficial femoral artery (SFA). PAD affects more than 8 million people in the U.S. alone and, by the age of 65, 12-20 percent of the population will develop PAD, according to the American Heart Association.

The SUPERB trial (Comparison of the SUPERA PERipheral System to a Performance Goal Derived from Balloon Angioplasty Clinical Trials in the Superficial Femoral Artery), a prospective, single-arm trial of 258 subjects at up to 40 U.S. sites, will be led by national co-principal investigators Kenneth Rosenfield, M.D., of Massachusetts General Hospital, Boston, MA and Lawrence Garcia, M.D., of Caritas St. Elizabeth's Medical Center, Boston, MA.

"The approval of this IDE marks a significant step forward toward understanding the potential benefits of the unique properties of the SUPERA stent," Dr. Rosenfeld said. "Members of the physician community have already shown a high level of interest in this novel stent platform and IDEV's commitment to generating prospective clinical data will help us demonstrate the promise of this device."

The objective of the trial is to demonstrate the safety and effectiveness of the SUPERA Interwoven Self-Expanding Nitinol Stent in treating subjects with obstructive SFA disease. SUPERA has demonstrated superior properties in engineering tests compared to nitinol laser cut slotted tube stents resulting in greater than four times the radial strength and 360 percent stronger crush resistance. The unprecedented increase in radial strength is due to the product's novel interwoven design, which adds strength without compromising flexibility. SUPERA also withstood more than 10,000,000 cycles of repeated bending - 120 degree flexion and compression loading fatigue testing, without a fracture.

"We believe SUPERA may prove to be a more durable solution and ultimately the gold standard for the treatment of PAD, a serious condition for millions of Americans and others around the world," said Tom Tully, Chairman and CEO of IDEV Technologies. "We are excited to begin enrolling subjects into the SUPERB trial and look forward to compiling data that will demonstrate the effectiveness of its unique design."

About IDEV Technologies, Incorporated

IDEV Technologies, Incorporated (IDEV) is an innovator and developer of next generation medical devices for use in the interventional radiology, vascular surgery and cardiology device marketplace. IDEV is based in Houston, Texas.

    Contact:  Thomas M. Tully, Chairman and CEO
              Christopher M. Owens, President and COO
              John Dame, Director of Finance
              IDEV Technologies Inc.
              (281) 333-1998


'/>"/>
SOURCE IDEV Technologies, Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Isolagen, Inc. Submits Biologics License Application for the Treatment of Wrinkles to the U.S. Food and Drug Administration
2. Rendell Administration Announces Health Research Grants From Tobacco Settlement Funds
3. ISTA Pharmaceuticals New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration
4. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
5. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
6. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
7. New AAHC Toolkit Available to Optimize Clinical Research Administration
8. New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration
9. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
10. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... May 25, 2016 As illustrated ... earlier this month, the numbers and momentum of cannabis ... climb into the billions, more research and development push ... Edition State of Legal Marijuana Markets Report  from from ... firm, much of the increase in sector is attributed ...
(Date:5/25/2016)... 25, 2016 ReportsnReports.com adds ... report that provides an overview on therapeutic pipeline ... various stages, therapeutics assessment by drug target, mechanism ... molecule type, along with latest updates, and featured ... players involved in the therapeutic development for Chronic ...
(Date:5/24/2016)...  Diana Russell suffers from a form of rheumatoid ... out.  This disease has put her in a wheelchair, ... grandchildren to leave her home.  Because of the size ... the wheelchair.  So if there is a family function, ... left to wait for the bus. Photo ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... Southland Log Homes , ... American timber frame barn kits, which can be found on its website at SouthlandLogHomes.com. ... American barn plans, and they highlight the craftsmanship of timber post and beam construction. ...
(Date:5/27/2016)... ... May 27, 2016 , ... With over 60 percent ... the demand for a sustainable product to aid in the rehabilitation process has steadily ... the recovery of individuals with hemiplegia due to stroke. , Ekso Bionics has now ...
(Date:5/27/2016)... ... ... Beleza Medspa has initiated a new program to assist active ... time that Coolsculpting is being used for for more than just cosmetic purposes. ... the prescribed body-fat standard, measured by the circumference-based tape method. The tape-test is ...
(Date:5/27/2016)... ... ... With a team of certified experts, Validation Center is ... GMP accreditation, Validation Center is also a registered authority of the international system ... Validation Center is ISO17025 accredited and only offers its clients the latest technology, ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot ... of defective respirators, according to court documents and SEC filings. A jury ... Becky Tyler v. American Optical Corporation, Case No. BC588866, Los Angeles County, California. ...
Breaking Medicine News(10 mins):